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1Abstract
Women who inherit a defective BRCA1 or BRCA2 gene have risks for breast/ovarian cancer 
that are so high and apparently so selective that many mutation carriers choose to have the most 
likely targets for cancer surgically removed.  Recent research has focused on better methods of 
treating such seemingly unavoidable hereditary cancers.  Prevention has received much less attention 
so a positive test result for a cancer gene leaves carriers with very limited options.  
In order to prevent BRCA1/2 related cancers, it may be important to understand why they 
seem to occur only in certain characteristic organs.   Results here show that mutations in a pathway 
depending on BRCA1/2 gene products magnify cancer risks from chronic infection and inflammation, 
making them especially important in selecting the site where hereditary cancer develops.   Control-
ling chronic infections and inflammation may be a helpful option to prevent or delay cancers in muta-
tion carriers.  
Introduction
Women who inherit a defective BRCA1 or BRCA2 gene have risks for breast/ovarian cancer 
that are so high and apparently so selective that many mutation carriers choose to have the most 
likely targets for cancer surgically removed [1-7].  Recent research has focused on better methods of 
treating the cancers that seem unavoidable.  Prevention has received much less attention so a posi-
tive test result for a cancer related mutation leaves carriers with very limited options. 
In order to prevent BRCA1/2 related cancers, it may be important to understand why they 
seem to occur only in certain characteristic organs.   Why would cancer just attack breasts and 
ovaries when every cell with a nucleus contains the same mutation?  Functionally, both BRCA genes 
are general cell requirements because they encode products essential for checkpoint controls and 
for DNA repairs.   How does inheritance of a defect in general cell requirements lead to cancers in 
specific target organs?  
Here the possibility is tested that infection and chronic inflammation direct inherited cancers 
to specific organ targets.  Evidence is overwhelming that chronic inflammation underlies many can-
cers and that some chronic infections can direct cancer to a specific organ.   For example, hepatitis 
viruses target the liver for cancer because the liver has receptors for hepatitis viruses.  Hepatitis B 
and C viruses do not cause cancer unless chronic inflammation follows infection, leading to DNA 
breaks [8, 9].  Many normal individuals recover and never develop liver cancer.  
Inherited cancer related mutations are rare, making risks from chronic inflammatory condi-
tions difficult to study.   Results from epidemiology were used to approach this problem.  Risks for 
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2cancers associated with inflammation in a specific organ were statistically combined from eleven 
published studies of known or likely mutation carriers.  The resulting statistical summaries of cancer 
relative risks included over 25,000 carriers of any testable mutation in DNA damage responses de-
pending on BRCA1 and BRCA2 gene products.  
The rarity of BRCA1/2 mutations made it necessary to include all testable components in the 
subroutine that depends on functional BRCA1 and BRCA2 proteins.  Figure 1 shows an approximate 
arrangement of the testable components in a model subroutine within the DNA damage response 
[10, 11]   Strong evidence supports the idea that inactivating a gene encoding any of these compo-
nents causes genomic instability and increases cancer risks.  All the components in the model partici-
pate in DNA damage responses that can be induced by reactive oxygen products from inflammatory 
processes.  These responses are double strand break repair by homologous recombination, repair of 
collapsed or stalled DNA replication forks, and prevention of hypersensitivity to DNA cross-linking 
agents.  Cancer genome sequences rarely inactivate more than one gene in the same sub-routine.  
Fanconi anemia (FA), ataxia-telangiectasia (A-T) and BRCA deficiency are hereditary can-
cer prone diseases caused by inactivation of one gene in the pathway containing BRCA1/2.  In each 
condition there are increased numbers of chromosome breaks, large rearrangements, and/or regional 
gains and losses in chromosomes [Fig. 1,12, 13].  Multiple steps in the repair of interstrand cross-links 
can fail when the FA pathway is compromised.  A-T patients have elevated risks for DNA damage in 
tissues undergoing inflammation [14] and FA patients over-express inflammatory genes and proteins 
[15].   Cells that are deficient in any one of eight FA core complex proteins are defective in monou-
biquitylation of FANCD2 and FANCI.  This defect causes chromosome breakages and FA hypersensi-
tivity to DNA cross-linking agents.  (See footnote to Fig 1).
Here, mutation carriers were found to have strikingly increased risks for cancers connected 
to known chronic inflammatory infections such as liver cancer, cervical cancer and stomach can-
cer.  Risks increase hundreds of times in homozygotes and up to several-fold in heterozygotes.  For 
BRCA1/2 related breast and ovarian cancers, cancer prevention data and evidence of immune re-
sponses suggest that chronic inflammation helps target these organs.  Inflammation also disrupts nor-
mal cellular organization and architecture, further favoring cancer.  Identifying and controlling chronic 
infections and inflammation may delay or prevent some hereditary cancers in mutation carriers.  
Materials and Methods
Identification of studies.  Epidemiologic data exists describing effects of mutation of 
numerous components within the DNA damage response network [16].    In order to reduce bias, 
explicit procedures [17] were used to systematically identify, appraise, summarize and statistically ag-
gregate relevant studies.  
Information sources.  PubMed and Google Scholar databases were systematically searched 
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Fig 1.  Simplified model for a double strand break repair subroutine emphasizing components that 
have epidemiologic studies measuring risks for multiple cancers beyond breast and ovarian cancer.   
Inactivation of ATM, Fanconi genes, or BRCA1/2 genes in hereditary conditions causes large chromo-
somal rearrangements, losses or gains of sections of chromosomes [11-14].  BRCA2 is the same as 
Fanconi component D1.  FA protein J is the same as BRIP1 (BRCA1 interacting protein 1).  Mutation 
of genes encoding any of numerous pathway components produces cancers in an overlapping distri-
bution of organs.  For example, mutations in NBS1, RAD50, ATM, BRCA1, BRCA2, CHEK2, FANCJ 
(BRIP1), or FANCN (PALB2) have each been associated with increased breast cancer risks.  Not 
shown are numerous interactions with other proteins and relationships to cell cycle checkpoints (see 
footnote).  The results reported here do not require that the pathway be linear and do not preclude 
participation by hormones.
Footnote  Details of this outlined pathway are still emerging but many publications place FA pro-
teins in the DNA damage network including BRCA1 and BRCA2 with activation by ATM and Rad3 
related (ATR) kinase  [e. g. 74, 75, 11].  Of the 13 FA proteins identified, eight of these, including 
FANC-A, -B, -C, -E, -F, -G, -L, and -M, form a multi-subunit nuclear FA core complex. In response to 
replication stress, the FA core complex promotes the monoubiquitylation of the FANCD2-FANCI 
heterodimer, which triggers their relocalization to sites of replication stress. Cells that are deficient 
in any one of the eight core complex proteins are defective in monoubiquitylation of FANCD2 and 
FANCI.  The FA core complex acts as the E3 ligase for FANCD2 and FANCI.  Any mutations that 
disrupt ubiquitylation of FANCD2 cause FA chromosome breakages and FA hypersensitivity to DNA 
cross-linking agents.  The other FA factors, FANCD1/BRCA2, FANCJ/BRIP, and FANCN/PALB2, are 
believed to function downstream of the FA core complex, possibly in the regulation of homolo-
gous recombination, also playing essential roles in lesion repair and replication fork recovery [74].   
BRCA1 is essential for the formation of nuclear foci, believed to be sites of DNA repair.
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4up to 2010, for original epidemiologic studies of non-breast, non-ovarian cancers vs. any defect in the 
model pathway in Fig. 1.  1250 articles published in the past 50 years were retrieved and copied to a 
database to facilitate computer searching and review.  Many bibliographies were also reviewed for ad-
ditional relevant references that may have been missed.  No language restrictions were imposed. 
Models for inflammation related cancers.  From these initial surveys, results were 
summarized for five cancers that have widely accepted and well-known links to chronic infection as 
follows.  Group 1: liver cancer associated with viral hepatitis such as hepatitis B or C; Groups 2-4:  
vulvar, cervical, and head and neck cancers, all associated with human papilloma viruses (HPVs); and 
Group 5: stomach (gastric) cancer associated with helicobacter pylori.
Included research articles analyzed.  Comparatively few publications describe cancer 
histories at sites other than breast or ovary from typed or probable mutation carriers.   No studies 
are available that directly determine the mutation status of every member of a large cohort of non-
breast/non-ovarian cancer cases.  Therefore, cohorts likely to have a mutation were included based 
on one or more risk factors for inheriting a mutation in the pathway containing BRCA1/2 proteins:  
These cohorts had a documented mutation in the family and/or numerous breast or other cancers 
at age <60.  Inherited defects were in FA proteins, BRCA1, BRCA2 or the upstream activator ATM.   
These cohorts were:  patients diagnosed with FA in specialized clinics;  all cases of FA from the lit-
erature;  families having members with positive BRCA1 or BRCA2 test results based in large part on 
breast cancers in women younger than age 60;   women from cancer registries with positive test re-
sults or high probabilities of being a BRCA1 or BRCA2 mutation carrier because of strong personal 
or family histories of breast and ovarian cancers at young ages;  male breast cancer patients younger 
than age 60;  cancers at age <60 in blood relatives of A-T patients.
Studies containing large numbers of cancers first diagnosed at age 60 or younger lessen the 
influence of sporadic cancers on effect measures.  Coincidentally, risk factors in normal populations 
for viral infections associated with specific cancers are also higher at younger ages.  
 Meta-analyses exclusion criteria.  Studies of groups having a known probability of carry-
ing a mutation <=20% (3 studies) were excluded.  Other exclusion criteria were > 20%  of subjects 
lost due to mortality, illness, refusal to participate, missing information, lost branches of family trees, 
dropouts, etc.  or some other preselection such as ignoring family branches likely to have cancer.  
Any of these criteria would potentially weight results for cancer survivors or people who never get 
cancer (7 studies) [18].   
For serial studies representing the same population, only the largest study was used (3 stud-
ies excluded).  Unpublished reports, single case reports and bone marrow transplant recipients were 
excluded.  At least three studies were required for meta-analysis.
Validity and Quality Assessment.  A high quality study was considered to have the fol-
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5lowing characteristics.  The study had to (1) have sufficient follow-up (1-10 years) (2) include inci-
dence data from >100 individuals for cancers beyond breast and ovarian cancer, (3) have a probability 
of mutation >20%, assuming a positive family history (4) provide relative risks for cancers beyond 
breast and ovarian, with confidence intervals (CIs) or sufficient data to allow calculation of RRs and 
CIs.  If exact mutation status was not known, the probability of carrying a BRCA1 or BRCA2 muta-
tion was estimated from other studies of similar populations or with the BRAC analysis risk calcula-
tor from Myriad Genetics.  
Data extraction.  The same standard protocol was followed to extract data from each 
included study.   Data were extracted blindly several times.  
Statistical analysis.   Included studies differed in the samples chosen as the mutation group 
and in the details of methods employed.  For meta-analyses, the random effects model was used since 
it allows for measured effects to vary across studies and estimates the inter-study effect variance 
with a simple non-iterative method [19].  Studies in meta-analyses were weighted according to this 
model [19].  Random and fixed effects calculations almost always gave identical or very similar results. 
All reported p values were derived from two-sided statistical tests. 
No assumptions were made about the risk for a cancer at any individual site unless the study 
reported this incidence.   The reasons for this were as follows.  Studies with the largest populations 
generally reported cancers at the most anatomic sites.   Most studies of heterozygotes reported an 
elevated overall cancer risk especially at early ages, often with some unidentified sites.  However ev-
ery study showed increased risks for multiple identified cancers, with some cancers again occurring 
at relatively early ages.  
Multi-variate and subgroup analyses.  The effects of different variables on the statistical 
results and the robustness of the results were measured by performing meta-analyses using many dif-
ferent combinations of studies and study arms.  
Heterogeneity testing evaluated whether the effect size in different subgroups (defined 
biologically or medically) varied significantly from the main effect.  The inconsistency of results across 
studies is summarized in the I² statistic, the percentage of variation across studies due to heterogene-
ity rather than chance.  An I2 value >50% generally indicates significant heterogeneity [20].  Hetero-
geneity was also calculated as non-combinability, and by a moment based method.  Heterogeneity 
estimates can have large uncertainty, especially for few trials and were interpreted cautiously.  
In some cases it was necessary to use cumulative control cancer incidences calculated us-
ing the NCI “DevCan” and “SEER” programs.  NCI  values were verified by comparison to published 
control values from numerous included references and always agreed well., showing that these 
control statistics were valid in these populations  All statistical results were further tested against 
independent evidence and theory.  There was no statistical evidence of publication bias [21] for final 
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6summary estimates (results not shown).  Statistical analyses and forest plots were performed with 
StatsDirect software (StatsDirect, Ltd 2008) and checked with RevMan software.
Results 
Initial search results for 5 cancer associated infection groups.  From the database of 
1250 articles, a shortlist was identified, consisting of 24 cohort studies containing relative risk data 
for cancers other than breast and ovarian in mutation carriers.  From the shortlist, 11 articles (some 
including several study arms) met inclusion criteria,  passed exclusion tests and met the criteria of 
quality assessment (Fig. 2).   The 11 studies were used in meta-analyses to determine whether BRCA 
pathway mutations led to elevated risks for five cancers, each with a known links to a chronic inflam-
matory infection.    Table 1 summarizes details of included studies [21-31], giving the characteristics 
of study participants and listing follow-up periods, cancers found, associated infections, effect mea-
sures,  and control values.  
Chronic inflammatory infections increase risks for cancers in some organs in mu-
tation carriers.  Table 1 shows RR data from mutation carriers [21-32] for five organ specific can-
Publications retrieved potentially related to 
BRCA pathway and dealing with cancers of 
liver, vulva, cervix, stomach, or head and neck 
area;  n=1250
Publications pertinent to hypothesis that 
infections/inammations magnify cancer risks
and select site for cancer.  Epidemiologic or 
basic science data; n=35
Publications from basic science 
relevant to hypothesis; n=11
Data summarized as 
corroborating data 
Table 3
Shortlist:  Publications providing relative risk data 
or allowing calculations of relative risks relevant to 
hypothesis that inammatory infections select liver, 
vulva, cervix, stomach, or head and neck as target 
sites for cancer in mutation carriers; n=24
Publications used in meta-analyses
extracted data shown in Table 1; n=11 
Publications excluded because 
probability of mutation in the 
population known to be <20%; n=3 
Publications excluded because other
publications with more data 
superceded them; n=3  
Publications excluded because of dropouts
or mortality of people likely to have 
cancers other than breast/ovarian  
or because of other pre-selection; n=7 
Fig 2. Flow chart showing numbers of publications retrieved at each stage containing data 
for cancers of liver, vulva, cervix, stomach or head and neck area. The numbers of publications 
in each category are indicated by values for n in each box.
Fig. 2. Flow chart showing numbers of publications containing relative risk data for 
cancers of liver, vulva, cervix, stomach or head and neck area.  At each stage of retrieval 
or analysis the numbers of publications are indi ated by values for n in each box.
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Gene variant 
/Reference
Study participants and follow up 
method/period
Infection and cancer 
target Effect measure [95% CI] 
No. cancers observed 
in carriers + possible 
carriers
Expected number of 
cancers as published or 
calculated using DevCan or 
SEER statistics
Adjustments, com-
ments
FA homo
zygote / Alter 
2003 [21] 
1289 FA patients from 80 years of literature 
data HBV or HCV liver RR = 574.1 (233.0 - 1414) 37 at median age 13 5/100,000 to age 20 [DevCan]
Survival was about 62% 
for cancers other than 
liver.  No survival correc-
tion was applied for liver 
cancer.
356 female surviving FA patients from 80 
years of literature data HPV cervix RR=76.61 (23.04-253.1) 3 at mean age 25 11/100,000 to age 25 [DevCan]. 
799 surviving FA patients from 80 years of 
literature data HPV head and neck RR=162.7 (91.83 - 287.7) 26 at mean age 28
20/100,000 for cancer of 
the oral cavity and pharynx 
[DevCan].
356 female surviving FA patients from 80 
years of literature data HPV vulva RR=1124 (550.3 - 2279) 10 at mean age 27
25/1,000,000 to age 30 and  
9/1,000,000 to age 25 [DevCan]. 
FA homo
zygote  / Kutler 
et al [22]
754 North American FA patients followed for 
20 years HBV or HCV liver RR =477.5 (184.2 - 1236) 39 at median age 13 5/100,000 to age 20 [DevCan]
Survival was about 62% 
for cancers other than 
liver.  No survival correc-
tion was applied for liver 
cancer.
228 surviving female N. Amer. FA patients  fol-
lowed for 20 years HPV cervix RR=239.2 (92.16 - 615.6) 6 at mean age 25 11/100,000 to age 25 [DevCan]. 
228 surviving female N. Amer FA patients  fol-
lowed for 20 years
HPV HNSCC (or EBV 
nasopharynx) RR=203.4 (110.1 -374.3) 19 at mean age 28
20/100,000 for cancer of the 
oral cavity and pharynx to age 
35 [DevCan].
228 surviving female N. Amer FA patients  fol-
lowed for 20 years
HPV vulva RR=1404 (649.0 -3001) 8 at mean age 27 25/1,000,000 to age 30 and  
9/1,000,000 to age 25 [DevCan]. 
FA homo
zygote  / 
Rosenberg et 
al 2003 [23] 
145 FA patients: 76 men and 69 women from 
up to 40 years of cancer incidence data HBV or HCV liver RR =275.9 (61.89 - 1215) 2 at median age 13 5/100,000 to age 20 [DevCan]
62% survival correction 
for tumors other than 
liver cancer
69 women from up to 40 years of cancer 
incidence data
HPV cervix RR=422.8 (105.9 -1597) 2 at mean age 25 11/100,000 to age 25 [DevCan]. 
145 FA patients: 76 men and 69 women from 
up to 40 years of cancer incidence data
HPV head neck (or EBV 
nasopharynx) RR=333.3 (139.2 -776.2) 6 at mean age 28
20/100,000 for cancer of the 
oral cavity and pharynx to age 
35 [DevCan].
69 women from up to 40 years of cancer 
incidence data HPV vulva RR=2791 (906.7-8033) 3 at mean age 27
25/1,000,000 at age 30 and  
9/1,000,000 at age 25 in normal 
women [DevCan].  
BRCA1 
heterozygote / 
Thompson et 
al 2002 [24] / 
11,847 individuals in 699 families,  18.9% 
(2245) were tested BRCA1 mutation carriers, 
9.3% (1106) were tested non-carriers, and 
71.7% (8496) were untested.  Cohort included 
women diagnosed with breast cancer at 
age<60. Average about 26 yrs follow-up,. Data 
from 30 centers in Europe and N America. 
HBV or HCV liver RR=4.06 [1.77 -9.34] 0 carriers; 17 untested 5.68 carriers; 5.03 untested.
Non-carrier RR set to 1.0. 
Paranasal sinus cancer 
among 65 “other cancers” 
O/E = 12/2.21 carriers; 
53/11.54 untested.   13 
cases peritoneal cancer as 
“other cancer.”
HPV cervix RR=3.84 [2.33 - 6.33] women < age 65 8 carriers; 28 untested 2.86 carriers; 11.82 untested
HPV (or EBV) Buccal 
cavity, pharynx. (HN-
SCC)
RR= 0.15 (0.06 to 0.40) RR 
“other” cancers = 7.40 [5.14 - 
10.66] 
0 carriers; 16 untested 3.42 carriers; 23.76 untested
h.pylori stomach RR=1.56 [0.91 - 2.68] 5 carriers; 33 untested 2.58 carriers; 24.80 untested
 Table 1 Details of cohort studies included in initial meta-analyses of known infection related cancers in BRCA pathway mutation carriers.
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Gene variant 
/Reference
Study participants and follow up 
method/period
Infection and cancer 
target Effect measure [95% CI] 
No. cancers observed 
in carriers + possible 
carriers
Expected number of 
cancers as published or 
calculated using DevCan or 
SEER statistics
Adjustments, com-
ments
BRCA2 
heterozy-
gotes  / Breast 
Cancer Linkage 
Consortium 
1999 [25]
3728 individuals including 50 men.  471 car-
riers; 390 non-carriers;  2186 untested.  596 
female breast cancer patients diagnosed 
under age 60.  Follow up began on later of 
01/01/1960  or birth until first cancer, death 
or drop out, age 85 or 12/31/1995.   Data 
from 20 centers in W. Europe and N. America.
HBV or HCV liver RR=4.18 [1.56 -11.23] 2 carriers; 2 untested 0.56 carriers; 1.45 untested Non-carrier RR set to 
1.0. RR =1.89 [1.5-2.3] 
all non-breast/ovarian 
cancers. 0-<65y. “Other” 
includes 2 nose cancers 
and several other sites O/
E= 4/1.59 carriers; 9/ 3.39 
untested.
HPV cervix RR= 1.29 (0.48 - 3.43) 2 carriers; 10 untested 3.73 carriers; 7.42 untested
HPV buccal cavity & 
pharynx (head neck)
RR=2.26 [1.09 - 4.58]  p=0.06 4 carriers; 8 untested 2.26 carriers; 5.47 untested
h. pylori stomach RR=2.59 [1.46 -4.61] 8 carriers; 14 untested 3.29 carriers; 8.52 untested
ATM heterozy-
gotes / Swift et 
al 1976 [31] 
27 A-T families from North America and 
Europe including 1639 individuals   In period 
01/01/1930 to 12/31/1973 death certificates 
and hospitalization records were collected to 
account for deceased relatives.  
HBV or HCV Liver, + 
bile duct + gallbladder 
(1 category until 1965)
SMR=5.00 (0.88 - 28.31) 
SMR=7.63 (1.24-46.9) for 1 
primary liver age 36
6 for bile duct and gall-
bladder, 1 primary liver 1.2.  
All infection/inflamma-
tion associated cancers 
caused at least one death 
in people under age 45.  
Other cancers did not.
[31]
HPV cervix RR= 3.03 (1.54 - 5.95) 8 with >=1 death at age 
< 45.  6/8 alive
322/100,000 age 50 [DevCan]. 
Normal peak age = 47.  
h.pylori stomach SMR=2.00 (0.72 -5.58) 10 (deaths) 5
BRCA1/2 
heterozygotes/ 
Evans et al 
2001 [29] 
2785 women from Thames cancer registry:  
primary cancer following 2 breast-, 2 ovarian- 
or 1 breast- 1 ovarian- cancer.  Diagnoses 
before 01/01/1971 followed to 12/31/1982  
Later diagnoses to 12/31/1996
HBV or HCV liver RR=1.84 (.05 -10.3) 1 0.54 
Low cervical cancer inci-
dence but high incidence 
of uterine cancer.  
HPV oropharynx RR=14.7 (1.73 -51.6) 2 0.14 
h. pylori stomach RR=1.53 (0.62 -3.16) 7 4.56 
BRCA2 
heterozygotes  
/ Hemminki et 
al. 2005 [28]
677 men diagnosed with breast cancer at 
age<56 pooled from 13 cancer registries.  
Followed after diagnosis for up to 20 - 54 y.  
Up to 44% estimated risk with positive family 
history of breast/ovarian cancer [32].
HBV or HCV liver RR=0.3 (0.0 - 2.53) 0 ( 0.01 in meta-analyses) 0.83 [DevCan] Risk depended on follow-
up period and age.  At 1-9 
yrs. follow-up, 6 liver can-
cers found in all groups 
SIR = 2.95 (1.08-6.41). 
HPV (or EBV) oral cav-
ity pharynx RR=1.94( 0.4 -5.66) 3 0.65
h. pylori stomach RR=3.82 (1.54 -7.87) 7 1.83
BRCA2
heterozygotes  
/ Johannsson et 
al 1999 [30]
383 male relatives and 345 females  87 tumors 
among 728 relatives.  Great majority of study 
groups were young.  Living family members 
followed from 01/01/1958 in cancer registries 
until at least 12/31/1995
HPV cervix SMR=4.21 (1.15-10.79) 4 0.95 Unlike BRCA2, both 
early family branches of 
BRCA1-cases had been 
excluded by the authors 
[30].   Authors excluded 1 
stomach cancer as a third 
tumor [30].
HPV (or EBV) oral cav-
ity (head neck)
SMR=4.17 (0.11 -23.26) 1 0.24
h.pylori stomach SMR=1.63 [0.34-4.75] 3 (4) 1.84
ATM heterozy-
gotes / Olsen 
et al 2005 [27]
1445 blood relatives of 75 patients with veri-
fied A-T in 66 Nordic families.  Most breast 
cancers at age<55.  712 women and 733 men.  
Mean observation = 31.8 years, both sexes 
and 32.15 yrs. women.
HBV or HCV liver RR=2.7 [1.37-5.44] 8 2.94 [SEER]
Mutation detection is 
problematic for ATM 
because of the large size 
of the gene.
HPV cervix RR=3.1 (1.42- 6.82) 6 1.92 [SEER]
h.pylori stomach RR = 4.62 (2.86-7.51) 17
3.67 [SEER];  2.93 to age 65; 6 
to age 75 [DevCan]
ATM heterozy-
gotes / 
Geoffrey-Perez 
et al 2001 [26]
34 families including 1423 relatives of A-T 
patients.  715 males and 708 females Obligate 
or potential ATM mutation carriers. Data en-
compass birth to mean age 40-45 at interview.
HBV or HCV liver
Obligate RR=4.55 [0.06 - 25.3]; 
50% heterozygotes
RR=7.69 [1.55 - 22.5]  25% 
RR=7.69[0.86,27.80]
1 Obligate
3 50% heterozygotes
Obligate heterozygotes 0.22; 
50% heterozygotes: 0.39   Cervical cancer was 
reported only as uterine 
cancer (cervix plus 
corpus).  Head and neck 
cancer was not reported.h.pylori stomach 
Obligate RR=1.61 [0.02 -8.97]; 
50% heterozygotes RR= 
2.22 [0.45-6.49] 25% RR= 
0.011[.000028 -4.5]
1  Obligate
3  50% heterozygotes
0  25% heterozygotes
Obligate heterozygotes 0.62; 
50% heterozygotes: 1.35.  
25% heterozygotes 0.91
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9Fig 3. Forest plots of RRs for infection/inflammation related cancers in carriers of any testable mutation
in the model subroutine in Fig.1 containing BRCA1 and BRCA2. RRs for homozygous FA patients
are shown in the left column and RRs for heterozygous mutation carriers in the right. 95% confidence inter-
vals are in parentheses after the RR value. A subgroup of HNSCC defined as cancer of the buccal cavity and 
pharynx or oral cavity gives RR=2.26 [1.22- 4.17] with 0% inconsistency. The results suggest RR and hetero-
geneity for HNSCC results are partly related to how HNSCC was defined (see text).
HNSCC HNSCC 
Vulva
10010
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100 1000
100,000
Rosenberg et al [23]
Kutler et al [22]
Alter [21]
Rosenberg et al [23]
Rosenberg et al [23]
Kutler et al [22,37]
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Rosenberg 
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Kutler et al [22]
Alter [21]
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Kutler et al [22]
Alter [21]
10010 1000 100,000
10010 1000 100,000
10
275.9 (61.89, 1215)
477.5 (184.2, 1236)
574.1 (233.0, 1414)
478.6 (255.9, 895.2)
333.3 (139.2, 776.2)
203.4 (110.1, 374.3)
162.7 (91.83, 287.7)
202.2 (138.0, 296.4)
422.8 
(105.9, 1597)
239.2 
(92.16, 615.6)
76.61 
(23.04, 253.1)
193.5 (74.81, 500.7)
2791 (906.7, 8033)
1404 
(649, 3001)
1124 (550.3, 2279)
1433 
(882.9, 2326)
Relative Risk Homozygotes Relative Risk Heterozygotes
Liver 
Liver 
Cervix
Cervix
Stomach 
Lower risk Higher riskHigher risk
1
1
1
Combined
Olsen et al [27]
Hemminki et al [28]  
Evans et al [29] 
Swift et al [31]
Breast cancer consortium [25]
Thompson et al [24] 
50% carriers Georey-
Perez 
et al [26] 
Obligate carriers
50% carriers 
25% carriers 
Obligate carriers
Johannsson et al [30]
1.29 (0.48, 3.43)
3.15 (2.27 - 4.35)
3.1 (1.42, 6.82)
3.03 (1.54 - 5.95)
4.21 (1.15, 10.79)
3.84 (2.33, 6.33)
0.2 0.5 1 2 5 10
Olsen et al [27]
Johannsson et al [30]
Breast cancer consortium [25]
Johannsson et al [30]
Breast cancer consortium [25]
Thompson et al [24]
Swift et al [31]
Swift et al [31]
Hemminki et al [28]
Evans et al [29]
Evans et al [29]
Hemminki et al [28]
Olsen et al [27]
Georey-Perez et al [26]
Breast cancer consortium [25]
Thompson et al [24]
Thompson et al [24]
2.38 (1.64, 3.45)
1.63 (0.34, 4.75)
2.22 (0.45, 6.49)
1.61 (0.02, 8.97)
4.62 (2.85, 7.51)
3.82 (1.54, 7.87)
1.53 (0.62, 3.16)
2.00 (0.72, 5.58)
2.59 (1.46, 4.61)
1.56 (0.91, 2.68)
0.1 0.5 1 2 5 10
0.1 0.2 0.5 1 2 5 10 100
3.67 (2.45, 5.48)
5.00 (0.88, 28.31)
1.84 (0.05, 10.30)
0.30 (0.01, 2.53)
2.70 (1.37, 5.44)
7.69 (1.55, 22.50)
7.69 (0.86, 27.80)
4.55 (.06, 25.30)
4.18 (1.55, 11.23)
4.06 (1.77, 9.34)
0.01 0.1 0.2 1 2 5 10 100
1.84 (0.39, 8.62)
4.17 (0.11, 23.26)
1.94 (0.40, 5.66)
14.30 (1.73, 51.60)
2.26 (1.09, 4.58)
0.15 (0.06, 0.40)
oropharyngeal cancer
25% carriers 0.011 (0.000029, 4.3)
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cers with well-known associations with chronic infection/inflammation – cancer of the liver, cervix, 
vulva, head and neck area, and stomach.  Figure 3 presents this data as graphical forest plots.  Table 
2 summarizes meta-analyses results and includes age of onset data.  Summaries in Table 2 represent 
2200 FA homozygotes, and 24, 272 “heterozygotes” as 19,765 BRCA1/2 heterozygotes or potential 
heterozygotes and 4507 A-T heterozygotes or potential heterozygotes.  
Risks increase hundreds of times for homozygotes and up to several times for heterozygotes.   
Thus an infection known to cause chronic inflammation in a specific organ is more likely to lead to 
cancer in that organ if an inherited mutation is present.  Onset of cancers associated with inflamma-
tion generally occurs earlier than in control populations (Table 2, column 3).   There is enough data 
available to make results robust so that changing individual study inclusions or exclusions causes only 
small differences in the combined meta-analysis RR values.  
 The conclusions here were not due to differences in study methodologies or to which gene 
mutated.   Data in Tables 1 and 2 and graphs in Fig. 3 give evidence that RR values do not depend on 
whether a mutation occurs in a different pathway component such as ATM vs. BRCA1/2 and that 
there are no obvious systematic errors.  For example, in blood relatives of A-T patients, cancers as-
sociated with infection or inflammation all caused at least one death at age <45 [31].
Heterogeneity.   Even though included studies used somewhat different methodologies, 
heterogeneity was usually zero or very low except for stomach cancer (I2= 42%,  moderate incon-
sistency).   Subgroup analysis suggested RR values and inconsistency in head and neck cancer studies 
(87.1%) may partly depend on differences in defining head and neck cancers.  Three studies reported 
HNSCC as cancer of the “buccal cavity and/or pharynx or oral cavity”.  A subgroup of these three 
studies gives a summary RR=2.26 [1.22- 4.17] with 0% inconsistency.  However, HPV is most clearly 
associated with oropharyngeal cancer (63% in the US), arising predominantly from the lingual and 
palatine tonsils.   The one study [29] that specifically reported oropharyngeal cancer also found the 
highest RR.  
Limitations.  Limitations of these results include comparatively small sample sizes because 
of the rarity of hereditary diseases.  Homozygous FA is especially rare so data originates from three 
studies involving about 2200 patients.  These studies were conducted before some FA proteins were 
known.   It was therefore necessary to consider FA proteins as a group.  This is justified biologically 
based on their interactions (See footnote to Figure 1).
The combined RR values for heterozygotes (Table 2) do not represent pure populations of 
heterozygotes.  No study tested every member of a cohort for a mutation.  Cohorts in some studies 
were not typed but were eligible for mutation testing based on personal or strong family histories.  
Meta-analyses results agree with independent evidence.  The first independent sup-
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Table 2 Meta-analyses of cancer risks linked to chronic inflammatory infections at specific organ tar-
gets in cohorts with mutations in the pathway containing BRCA1 and BRCA2 gene products
Gene(s) and 
number of 
patients 
included in 
meta-anal-
yses
Organ 
target
Median age pa-
tients vs. median 
age general pop-
ulation or other 
comparison
Summary relative 
risk, 95% confidence 
interval and p value
Number of 
studies in 
meta-analysis 
or study arms 
[reference] 
Cumulative inci-
dence in control 
patients, patient 
age and from Dev-
Can and/or SEER
2200 FA gene 
homozygotes, 
including 1010 
females
Liver 13 vs. 66-67 478.6 (255.9, 895.2) 
p<0.0001 3 studies includ-
ing one with 
summaries of 
80 years of data 
from the litera-
ture and another 
with 20 years of 
observation  [21-
23, 37]
5 per 100,000 cumu-
lative to age 15-20 
Cervix 25 vs. 47
193.5 (74.81, 500.7)
P<0.0001
11 per 100,000 
women cumulative 
to age 25
Vulva 27 vs. 72
1433 (882.9, 2326) 
p<0.0001
25 per 1,000,000 
women cumulative 
to age 30 
Head 
neck 28 to 33 vs. 74
202.2 (138.0, 296.4) 
p<0.0001
20 per 100,000 cu-
mulative to age 35 
24, 272 
heterozygotes 
as19,765 
BRCA1/2 
heterozygotes 
or potential 
heterozygotes 
and 4507 ATM 
heterozygotes 
or potential 
heterozygotes
Liver
6 liver - biliary sys-
tem cancers in 907 
members of ATM 
families, some fatal 
before age 45[31]
3.67 (2.45, 5.48)
p<0.0001
8 studies / study 
arms [24-29, 31] 
Country specific 
cancer rates as ex-
tracted from original 
publications,  with 
DevCan and SEER 
data both as neces-
sary and for compa-
rision
Cervix
2 cervical cancers 
in 454 ATM females 
fatal before age 45 
[31]
3.15 (2.27,4.35) 
p=.0016
5 studies / study 
arms [24,25, 
27,30, 31]
Stom-
ach
Before age 56  
(BRCA2 carri-
ers) vs. age 71 in 
controls
2.38 (1.64, 3.45)
p<0.0001
9 studies / study 
arms [24-31]
Head 
neck
Half of head and 
neck cancer pa-
tients with reduced 
or absent ATM 
expression were 
younger than 50 
years old.
2.26 (1.22, 4.71)
p=0.0093 for subgroup 
with 0% inconsistency)  
1.84 (0.39, 8.62) p=0.44 
with 87.1% inconsis-
tency for all studies of 
different cancer sites in 
head and neck.
5 studies / study 
arms [24,25, 28-
30,]
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port for the above results was obtained by verifying that lymphocyte infiltration is present in all five 
organ specific cancers as a sign of chronic inflammation.   Search results (Fig. 2) also included inde-
pendent data supporting results summarized in Table 2.  Table 3 lists this independent evidence from 
11 publications in addition to those used for statistical summaries. 
The first paragraph in Table 3 indicates that the pathway containing BRCA1/2 is the preferred 
method to repair DNA lesions generated by inflammatory products.  BRCA-FA dependent homolo-
gous recombination is initiated by fork breakage at adducts produced by peroxynitrite derived from 
macrophages [33].   Peroxynitrite oxidizes guanine in DNA producing an O-acyl-isourea structure 
that then reacts with proteins such as histones or glycosylases to form DNA protein adducts.   The 
lesions are so bulky that BRCA-FA dependent homologous recombination occurs in preference to 
nucleotide excision repair [33].   Impaired homologous recombination would thus favor dangerous 
gene rearrangements if less specific repair methods then operate [11].  There are also many oppor-
tunities for interstrand cross-links.  Inflammatory products from immune defenses may favor cancer 
if essential DNA damage response defenses have been weakened because of an inherited mutation 
[34]. 
 Table 3 gives further examples of completely independent evidence [35-44] showing that a 
BRCA pathway mutation magnifies cancer risks from chronic inflammation, which then becomes a 
major factor in determining the organ targeted by cancer.  
Ovarian cancers need not originate in the ovary.  Table 4 summarizes evidence from 
26 studies [45-72] that inflammation targets ovary and breast in mutation carriers.  Regardless of 
mutation status, most ovarian cancer begins in the fimbriae - fingerlike projections terminating the 
Fallopian tubes where the ovum released from the ovary is collected.  Fimbrial cancers are difficult 
to distinguish from ovarian cancer because of large areas of intimate contact between fimbria and 
ovary.  The fallopian tube cancer designation requires a dominant mass and evidence of an early 
cancer there.  However ovarian tumor bulk may be greater.  In the past, ovarian and tubal cancers 
were grouped and coded together [25].  Tubal ligation protects against ovarian cancer in both mu-
tation carriers and non-mutation carriers (Table 4).   Tubal ligation commonly removes sections of 
tubes between the uterus and fimbria,  presumably preventing infection/inflammation from reaching 
the fimbriae/ovaries.   Ovulation itself may also contribute to inflammation by causing oxidative injury 
to both the ovary and the fimbria.  Inhibiting ovulation by oral contraceptives decreases cancer risk 
(Table 4).  At the site of ovum release, leukocyte invasion, release of nitric oxide and inflammatory 
cytokines, vasodilation, DNA repair, and tissue remodeling (resembling wound healing) all occur [55]. 
Table 4 also shows other associations between infection / inflammation and fimbrial-ovarian 
cancer.  These include evidence of inflammation in fallopian tubes and in ovaries removed during 
prophylactic surgeries and ovarian cancer associated with use of perineal talc.   Anti-inflammatory 
NSAIDs reduce ovarian cancer risk in nulliparous women [56].
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Table 3 Independent corroboration that mutations in the BRCA1/2 sub-
routine magnify risks for cancers with known links to infection / inflam-
mation 
Homologous recombination repair requiring the BRCA-FA pathway is essential to repair in-
flammation related DNA-protein adducts in mammalian cells and to repair other inflammation 
related DNA damage [33 and see text]. 
Cells with a defective BRCA pathway are unduly susceptible to viral cancers.  Transformation 
of FA fibroblasts by viral SV40 T-Ag occurs readily and is 3 – 50 times more frequent than in 
normal cells.  Correction of the Fanconi defect reduces transformation potential [35].  Activa-
tion of FA proteins is an early host cell response to HPV infection.  Expression of high risk 
HPV oncoproteins in Fanconi deficient cells leads to accelerated chromosomal instability [36].  
FA patients are highly susceptible to HPV cancer such as vulvar, cervical and anal cancers[21].  
54% of patients who develop these cancers have a history of HPV-associated condylomas 
[37].    Odds of finding HPV infection in head and neck squamous cell carcinoma in Fanconi 
anemia are 8.85 (CI=1.90, 54.19) [37]  
Hepatitis C viral proteins down regulate FA protein J, (Bach1) a helicase that interacts with 
BRCA1 (Fig. 1) [38].  The hepatitis C viral protein NS3/4A interacts with ATM altering its 
properties [39].  Inactivation of BRCA2 is common in hepatocellular carcinoma, a cancer 
commonly associated with hepatitis viruses [40].  
Fancc-deficient mice exhibit enhanced inflammatory response and are hypersensitive to LPS-
induced septic shock as a result of hemopoietic suppression. This exacerbated inflammatory 
phenotype is intrinsic to the hemopoietic system and can be corrected by the re-expression 
of a wild-type FANCC gene, suggesting a potential role of the FANCC protein in innate im-
munity [41]
Some pathway defect is frequently found in cervical cancers (mainly caused by HPVs).  A 
mutated BRCA1 gene was detected in 13/17 precancerous lesions of the cervix [42]. 42% (34 
of 81) of cervical cancers had an allelic imbalance at a locus in 11q23.1 (near or including the 
ATM gene) [43].  
In the Polish population, a family history of ovarian cancer and stomach cancer is associ-
ated with germ-line BRCA2 mutations [44].  The frequency of the BRCA2 6174del mutation 
amoung consecutive Jewish patients with stomach cancer is about 5 times higher than in the 
general population.
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The presence of intra-epithelial CD8+ T-cells significantly correlates with loss of BRCA1 [58, 
55].  This association links inflammation to mechanisms of genomic instability [58].   Infiltration of 
ovarian cancers by T-cells may be inflammation marking ovaries for cancer as it does in other organs, 
even predisposing to loss of BRCA1 [58].   An alternate explanation is that the infiltrate represents 
an immune response that favors further genomic instability in the tumor.  
  Prophylactic removal of ovaries increases risks for primary peritoneal cancer (Table 4), 
which occurs in up to 5% of patients.  One explanation is that wound healing increases risks for can-
cer in surrounding tissues.  Inflammation is an essential process that occurs early in wound healing.
Breast cancer.   T-cell lobulitis is frequently found in morphologically normal breast lobules 
removed during prophylactic mastectomies [60-61].  The failure to find any premalignant or malignant 
lesion suggests that there is an immune response before the onset of hereditary breast cancer.   
T-lymphocyte infiltrates predominate in hereditary breast carcinomas [60-62],  unlike diabetic 
lobulitis where B-cells predominate.  In other systems, T-cells produce growth regulatory molecules 
epidermal growth factor (EGF) and fibroblast growth factor (FGF) which are both implicated in 
breast cancers.  BRCA1 associated breast cancers have more and denser lymphocytic infiltration 
than sporadic cancers in a matched control group (Table 4).   Some extracted infiltrating lymphocyte 
populations may have tumor killing activity in vitro, suggesting the tumor overcomes such protec-
tive functions.   A T-lymphocytic infiltrate is also closely associated with medullary breast carcinoma 
(Table 4), a rare cancer that is more frequent in BRCA1/2 mutation carriers.   The medullary cancer 
infiltrate contains CD4+ and CD8+ T-cells but few tumor killing NK cells [65].   
There is a strong signature for an interferon induced pathway in some breast cancer, ovar-
ian cancer and childhood leukemia.  This “infection associated gene signature” suggests a deregulated 
immune or inflammatory response to some pathogen (Table 4).   In BRCA1/2 carriers, lymphoid cells 
are themselves at high risk for becoming malignant [11].  Hematopoietic malignancies would make 
immune responses in mutation carriers less effective in clearing infection and removing abnormal 
cells [60, 63].  
One candidate source for infection / inflammation in breast cancer are human endogenous 
retroviruses (HERV).  HERV-like sequences are integrated within the human genome.  Expression of 
these sequences can cause inflammatory responses.  Strong antibody and T-cell responses to HERV 
antigens have been found in women with early onset breast cancer and other breast cancer patients 
(Table  4).    
Five meta-analyses including up to 91 studies, involving millions of subjects find that NSAIDs 
protect against breast cancer (Table 4).
Breast tissue of women with a background of familial breast cancer have breast fibrosis and 
less breast differentiation than control or normal tissues [63].   This could result from infection/in-
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Table 4  Evidence that inflammation targets ovary and breast for hereditary cancers
Cancer Intervention, 
risk  factor, 
characteristic
Evidence of association with inflammation 
and Effect on risk in mutation carriers if 
known.
Number of mutation carriers and risks Effect on risk in women with no 
known mutation in the pathway 
containing BRCA1/2
Ovarian / 
Fimbrial  
Removal of fallo-
pian tubes as can-
cer risk reduction 
surgery
Contralateral tubes from 14 fallopian tube cancers all 
had healed chronic inflammation (p=.0089) suggesting 
bilateral tubal disease preceding the cancers [45]. 
Depending on cancer detection method and study design, 
40-100% of tumors classified as ovarian cancers were fim-
brial cancers[46].  7 consecutive cancers in BRCA+ women 
all originated in the fimbrial or ampullary region of the tube 
[47]. 12/28 (43%) fallopian tube cancers were from women 
with BRCA mutations.  Median age about 8 years < sporad-
ic cases (57 vs. 65) and no exclusively proximal disease [48] 
Risk for fimbrial cancer in normal women is 
not known.   
Ovarian Tubal ligation
In mutation carriers, pooled Odds ratio OR = 0.69 
(95% CI = 0.55-0.85).  For BRCA1 carriers Hazard 
ratio, HR=0.49 (0.22-0.80) [49-53] Fallopian tube 
cancer originates in distal tube [48, 54]  This suggests 
infection/inflammation must travel through the tube.
OR based on a total of 3070 BRCA1 and BRCA2 carriers. 
HR from 2,281 BRCA1 and 1,038 BRCA2 carriers [53]
30 publications show an inverse association 
with ovarian cancer risk based on data from 
hundreds of thousands of women.  
Ovarian Oral contraceptives
Hazard ratio, 0.52; ( 0.37-0.73; P = 0.0002)for BRCA1 
carriers who had ever used OC.  Increasing duration 
of OC use was associated with a reduced ovarian 
cancer risk (P trend = 0.0004). [53]
2,281 BRCA1 and 1,038 BRCA2 carriers
In high-income countries, 10 years OC use 
reduced incidence at age <75 from 1.2 to 0.8 
/100 users and mortality from 0.7 to 0.5.  ~2 
ovarian cancers and one death at age< 75 are 
prevented/5000 woman y. use [55].  
Ovarian
Intraepithelial 
tumor infiltrating 
lymphocytes, mac-
rophages
Statistically significant association [58,55] between 
ovarian cancer and lymphocyte infiltration in BRCA1 
mutation carriers.  This links inflammation to genomic 
instability (see text).
17/ 18 cases with BRCA1 mutation or epigenetic silencing 
of BRCA1 expression had intraepithelial CD8+ tumor-
infiltrating lymphocytes [58].
11 of 19 cases without BRCA1 abnormalities 
(P=0.019) had tumor infiltrating lymphocytes 
[58].  Macrophages may also be found in 
ovarian tumors [55].
Ovarian
Use of talc in the 
perineal region
It is well known that talc causes inflammation in the 
pleural cavity.  Some talc can contain asbestos fibers.  
Talc reaches the upper abdominal cavity and is de-
tected in surgically removed ovaries.
Risk in mutation carriers has not been studied. RR as high as 4.8 (2.1-11)[57]
Ovarian Use of NSAIDS Well known anti-inflammatory agents Not separately studied
487 ovarian cancer cases and 2653 controls.  
Nulliparous OR=0.47(0.27-0.82) Never users 
of oral contraceptives OR=0.58 (0.42-0.80)
[56]
Ovarian
Prophylactic sur-
gery oophorectomy 
in mutation carriers
6/324 women who underwent prophylactic removal 
of ovaries developed primary peritoneal carcinoma 
[59]  This may be an example of cancer in surrounding 
tissues associated with inflammatory processes during 
wound healing.
324 [59].  Also 13 cases of Peritoneal cancer as the most 
frequent site of “other cancers” in a cohort of BRCA1 
women [24]
Breast
Breast inflammation 
as lobulitis
21/41 prophylactic mastectomy specimens.   Frequent-
ly found before onset of cancer in high risk women 
[60] 
41 patients who underwent prophylactic mastectomy [60] 21/41 vs 8/82 controls (p < 0.0001) [60].
Breast
Breast inflamma-
tion as lymphocyte 
infiltrate in prophy-
lactic mastectomies
BRCA1/2 mutation carriers have a denser lymphoid 
infiltrate in breast cancers compared with their 
matched, sporadic control group (P= 0.02) [61].
10/17 with infiltrate varying from mild to dense vs. 13/43 
cancers in controls without mutation [61]
3/52 cancers from women with “no mutation 
detected” had lymphoid infiltrates vs. 23/157 
in matched sporadic controls [61].
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Cancer Intervention, 
risk  factor, 
characteristic
Evidence of association with inflammation 
and Effect on risk in mutation carriers if 
known.
Number of mutation carriers and risks Effect on risk in women with no 
known mutation in the pathway 
containing BRCA1/2
Breast
Lymphocyte infil-
trate in BRCA1 
breast cancer
Cancers associated with BRCA1 mutations had higher 
mitotic counts (P = .001), and more lymphocytic infil-
tration (P = .002) than sporadic (i.e., control) cancers 
[62, 61].
OR=1.90 (1.31-2.76) mild and 2.46(1.26-4.79) prominent,  
219 observations from 114 subjects with mutations in the 
BRCA1 gene.   141 observations from 73 subjects with 
BRCA2 mutations did not give statistically significant effects. 
1046 observations from 528 control subjects with cancers 
unselected for family history [62]  
See row above and row below
Breast
Mononuclear cells 
(T, B-cells, mac-
rophages)
Transitions from normal breast to benign proliferative 
breast disease to ductal carcinoma in situ to infiltrat-
ing ductal carcinomas were associated with signifi-
cantly increased mean densities of inflammatory cell 
infiltrates [64]
Large increases in infiltrates in precursor 
form benign proliferative breast diseases 
compared to stroma.  T-cells 82 vs 4; B-cells 
26 vs 3.  Smaller increases in DCIS and inva-
sive diseases [64].  
Medullary 
Breast 
Intraepithelial 
tumor infiltrating 
lymphocytes
Medullary breast cancer is closely associated with a 
dense lymphocyte infiltrate[65]  13/13 cases had a 
dense T-lymphocyte infiltrate, with few NK cells (see 
text). Medullary cancer is more frequent in BRCA1/2 
mutation carriers.    
 13  Disease is rare in normal women
Breast 
Genes expressed 
primarily in lym-
phocytes
Data was consistent with BRCA1 positive tumors 
having higher lymphocyte infiltrate  based on higher 
expression of lymphocyte specific genes [66]. 
16/18 BRCA1 tumors [66]
Breast 
Interferon regu-
lated genes
One explanation is an immune response to viral infec-
tion or inflammation [67]  Genes important for im-
munity to infection and for removal of abnormal cells 
are overexpressed in normal parous women but are 
not overexpressed in BRCA1 carriers [68]
BRCA1 expression is essential to upregulate a group of 
IFN-g regulated genes  including an anti-viral protein (8-
fold) and an antigen presentation protein (2-fold)[69]
40% of 96 breast cancer samples had a strong 
signature for an interferon induced pathway 
[67]
Breast
HERV  viral protein 
expression
Strong evidence of ongoing immune response in 
breast cancer patients including antibody, T-cell re-
sponses against HERV antigens and gamma interferon 
induction [70]. HERV was reactivated in 88% of breast 
cancer samples including young women at greater 
risk for BRCA1/2 mutations but not in controls [70].  
RNA Expression from retrovirus found in high titer in 
circulating blood from 20 breast cancer patients [71] 
BRCA1/2 status was not determined but most breast can-
cers occurred in younger age patients .  26/36 patients were 
age <=55 and 15/36 age < 50 [70]
8 to 25 normal controls [70]
Breast NSAIDS Well-known anti-inflammatory drugs
RR=0.88 (0.84-0.93) based on meta-analysis 
of 38 studies [72]  Five meta-analyses involv-
ing millions of subjects  and up to 91 stud-
ies find that NSAIDs protect against breast 
cancer.
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flammation mediated cell and DNA damage or deficiencies in genes required for differentiation.   
Discussion
Hepatitis or human papilloma viruses or h. pylori select specific organs for cancer because 
their organ targets have specific receptors on the surface of cells.  Then transcription factors or 
other host conditions that permit the infection also influence whether chronic inflammation and 
then cancer occurs.  
Not only do genetically related cancers typically occur at young ages but specific cancers 
associated with viral infections have peak occurrences in younger victims.  Viral hepatitis and HPV 
infections have peak incidences in younger people where risk factors are typically greater and risky 
behavior is more frequent.  The peak age for cervical cancer in women is age 47.  Head and neck 
cancer associated with HPV infection in normal males occurs as cancer of the of the oropharynx and 
tonsils with peak ages 55-59 [NCI SEER data].  In contrast, many sporadic cancers that are not as-
sociated with known infections typically occur at older ages.
Inherited defects in a DNA repair subroutine containing BRCA1/2 gene products amplify 
risks for cancers due to chronic infection or inflammation.  This is a mechanism of targeting spe-
cific organs for cancer.  Molecules that break DNA, including superoxide, hydrogen peroxide, singlet 
oxygen, and nitrogen oxides are released from activated phagocytic inflammatory cells such as mac-
rophages,  monocytes, neutrophils, etc.  that are present in tumors.  Lymphocytes and other cells are 
attracted to the site.  Many nearby cells are injured or killed.  Cellular DNA in this environment is 
continually damaged and must be repaired or replaced, thereby increasing risks for further dangerous 
mutations.  
The cancer targets here include hormone responsive organs in the female reproductive 
system and the liver where they are metabolized.  In a prostate cancer model, hormone receptor 
complexes move regions of chromosomes into close proximity and increase risks for site specific 
cancer related gene fusions after DNA double strand breaks are induced by DNA radiation damage 
[73].   The pathway containing BRCA1/2 is probably essential to prevent some cancer related gene 
rearrangements [11].   A repair-deficient genetic background magnifies cancer risks from chronic 
infection and inflammation, which can then become especially important reasons that a particular 
organ develops cancer.  
Conclusion  
Mutations in a DNA repair subroutine dependent on BRCA1/2 genes magnify cancer risks 
from chronic infection and inflammation, making them especially important in selecting the site 
where hereditary cancer develops.   Controlling chronic infections and inflammation may be a helpful 
option to prevent or delay cancers in mutation carriers.  
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